CN Patent

CN117210468B — 靶向调控PCSK9基因表达的siRNA及其应用

Assigned to Hangzhou Tianlong Pharmaceutical Co Ltd · Expires 2024-02-20 · 2y expired

What this patent protects

本公开涉及靶向调控PCSK9基因表达的siRNA及其应用。实验结果显示，一些交替修饰和特定模板修饰的寡核苷酸序列，能够显著抑制PCSK9表达，可用于开发治疗PCSK9相关疾病的药物。

USPTO Abstract

本公开涉及靶向调控PCSK9基因表达的siRNA及其应用。实验结果显示，一些交替修饰和特定模板修饰的寡核苷酸序列，能够显著抑制PCSK9表达，可用于开发治疗PCSK9相关疾病的药物。

Drugs covered by this patent

Patent Metadata

Patent number
CN117210468B
Jurisdiction
CN
Classification
—
Expires
2024-02-20
Drug substance claim
No
Drug product claim
No
Assignee
Hangzhou Tianlong Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.